13F Holdings
中文EN

RCKT ROCKET PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1281895 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY93.3%
TTM EPS YoY93.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-5.0%
ROA-4.1%
ROIC (approx.)-60.4%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets22.1%
Debt / equity0.09x
Current ratio7.26x
Interest coverage-100.61x

Cash quality & payout

Operating cash flow / net income9.84x
Accruals ratio36.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0$0$0$0
R&D expense$142.01M$171.24M$186.34M$165.57M$125.48M
SG&A expense$86.50M$101.96M$73.32M$58.77M$41.77M
Operating income-$231.75M-$273.20M-$259.66M-$224.34M-$167.25M
Interest expense$1.89M$1.89M$1.88M$1.86M$2.98M
Pretax income-$223.12M-$258.75M———
Income tax$0$0$0——
Net income-$223.12M-$258.75M-$245.59M-$221.86M-$169.07M
EBITDA-$222.85M-$266.00M-$254.76M-$220.44M-$164.05M
EPS (basic)-2.01-2.73-2.92-3.26-2.67
EPS (diluted)-2.01-2.73-2.92-3.26-2.67
Weighted avg. shares (diluted)111.12M94.81M84.01M68.15M63.24M
Balance sheet
Cash & equivalents$77.56M$165.00M$57.28M$141.86M$234.04M
Short-term investments$111.37M$208.70M$317.27M$215.88M$156.05M
Inventory$0————
Current assets$192.73M$378.18M$378.22M$364.06M$392.06M
PP&E, net$28.17M$36.79M$39.17M$29.01M$22.30M
Goodwill$39.15M$39.15M$39.15M$39.20M$30.82M
Intangibles$25.15M$25.15M$25.15M$25.72M$0
Total assets$330.45M$527.70M$566.34M$551.81M$497.02M
Current liabilities$30.21M$40.68M$48.51M$39.17M$22.17M
Long-term debt$0————
Total debt$0————
Total liabilities$53.23M$64.47M$73.77M$62.12M$42.30M
Shareholders' equity$277.22M$463.23M$492.57M$489.69M$454.72M
Net debt-$77.56M————
Shares outstanding108.32M106.45M90.28M79.12M64.51M
Cash flow statement
Operating cash flow-$190.01M-$209.72M-$194.92M-$178.14M-$121.16M
Capital expenditure$440,000$5.86M$16.44M$8.36M$7.62M
Free cash flow-$190.45M-$215.59M-$211.35M-$186.50M-$128.78M
Investing cash flow$103.77M$131.71M-$98.07M-$69.33M$18.85M
Financing cash flow$148,000$185.74M$208.40M$155.29M$37.68M
Depreciation & amortization$8.90M$7.20M$4.90M$3.90M$3.20M
Stock-based compensation$37.06M$43.92M$39.41M$31.01M$29.24M
Share buybacks————$0

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.